Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    11849228 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Conditions: Hematologic Malignancies;   Acute Myeloid Leukemia;   Lymphoid Leukemia;   Chronic Myeloid Leukemia;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Myelodysplastic Syndromes
Intervention: Drug: StemEx®

Indicates status has not been verified in more than two years